125 related articles for article (PubMed ID: 23547076)
1. Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
Kantarjian H; Wilson W; Ravandi F; Estey E
J Clin Oncol; 2013 May; 31(14):1795-6. PubMed ID: 23547076
[No Abstract] [Full Text] [Related]
2. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
Sekeres MA; Steensma DP
J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302
[No Abstract] [Full Text] [Related]
3. Reply to H. Kantarjian et al.
Steensma DP; Sekeres MA
J Clin Oncol; 2013 May; 31(14):1796. PubMed ID: 23802242
[No Abstract] [Full Text] [Related]
4. Concise drug review: azacitidine and decitabine.
Derissen EJ; Beijnen JH; Schellens JH
Oncologist; 2013; 18(5):619-24. PubMed ID: 23671007
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
[No Abstract] [Full Text] [Related]
6. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
[No Abstract] [Full Text] [Related]
7. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
[No Abstract] [Full Text] [Related]
8. Evidence for a role of decitabine in the treatment of myeloid sarcoma.
Gornicec M; Wölfler A; Stanzel S; Sill H; Zebisch A
Ann Hematol; 2017 Mar; 96(3):505-506. PubMed ID: 27817041
[No Abstract] [Full Text] [Related]
9. Decitabine studies in chronic and acute myelogenous leukemia.
Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
[No Abstract] [Full Text] [Related]
10. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
[TBL] [Abstract][Full Text] [Related]
11. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
12. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
[No Abstract] [Full Text] [Related]
13. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
14. The role of hypomethylating agents in the treatment of elderly patients with AML.
Al-Ali HK; Jaekel N; Niederwieser D
J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
[TBL] [Abstract][Full Text] [Related]
15. Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine.
Mulay S; Bauer F; Boruchov A; Bilgrami S
Leuk Lymphoma; 2011 Feb; 52(2):341-3. PubMed ID: 21142783
[No Abstract] [Full Text] [Related]
16. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
17. MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.
Milne TA
Haematologica; 2014 Sep; 99(9):1405-7. PubMed ID: 25176980
[No Abstract] [Full Text] [Related]
18. Azacitidine in adult patients with acute myeloid leukemia.
Schuh AC; Döhner H; Pleyer L; Seymour JF; Fenaux P; Dombret H
Crit Rev Oncol Hematol; 2017 Aug; 116():159-177. PubMed ID: 28693797
[TBL] [Abstract][Full Text] [Related]
19. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
[No Abstract] [Full Text] [Related]
20. Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.
Gruber E; Franich RL; Shortt J; Johnstone RW; Kats LM
Leukemia; 2020 Dec; 34(12):3388-3392. PubMed ID: 32655143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
